Evidence map›Paper›PMID 42356584›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Discovery of Macrocyclic Peptide Inhibitors Targeting MYC Oncoprotein via mRNA Display.

Jinzhu Chen, Fanglin Li, Chenguang Yuan, Xiaoling Geng, Yu Zhang, Qiurong Ding, Yan Chen

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinzhu ChenShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.ORCID 0009-0002-6476-431X
Fanglin LiShenzhen Sungening Biological Co., Ltd., Shenzhen 518172, China.
Chenguang YuanShenzhen Sungening Biological Co., Ltd., Shenzhen 518172, China.ORCID 0000-0002-7136-9660
Xiaoling GengSchool of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Yu ZhangSchool of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Qiurong DingShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.ORCID 0000-0001-9906-6787
Yan ChenShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.ORCID 0000-0002-6630-0693

Funding

Hangzhou Institute for Advanced Study no numberNational Natural Science Foundation of China 32230047
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

macrocyclic peptidemRNA displayMYCtumor treatmentundruggable target

Identifiers

PMID42356584
PMCPMC13304548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.